Literature DB >> 26701752

The GLP-1 agonist exendin-4 attenuates self-administration of sweetened fat on fixed and progressive ratio schedules of reinforcement in rats.

Kimberly A Bernosky-Smith1, David B Stanger2, Alexandria J Trujillo2, Luke R Mitchell3, Rodrigo A España3, Caroline E Bass4.   

Abstract

GLP-1 agonists such as exendin-4 (EX4) are used in the treatment of type-2 diabetes and have the additional benefit of promoting weight loss. GLP-1 agonists decrease feeding through peripheral effects, but recent evidence suggests they may also influence sweet or high fat preference, as well as motivation to obtain these tastants. Yet it remains unclear how GLP-1-induced alterations in food preference influences decreases in overall feeding. The current study sought to determine if EX4 affects the reinforcing strength and consumption of a highly palatable sweet/fat reinforcer. Rats were trained to self-administer sweetened vegetable shortening (SVS) under fixed (FR) and progressive ratio (PR) schedules of reinforcement. EX4 (0.3-2.4μg/kg, i.p.) administered one hour prior to operant sessions significantly reduced responses for SVS under both FR and PR schedules, although the lowest active dose (0.6μg/kg) significantly suppressed FR responding only. EX4 also dose dependently decreased locomotor activity (0.6-2.4μg/kg doses), but did not enhance acute kaolin intake, suggesting that nausea did not influence the self-administration results. Analysis of ED50 values show that EX4 is more effective at inhibiting FR responding versus PR, indicating that EX4 may have more potent effects on amount consumed versus motivation for SVS. Although EX4 caused generalized locomotor suppression, these results do not fully explain the decreases in operant responding. For example, a dose of EX4 (0.6μg/kg) that significantly suppressed locomotor activity did not affect the mean total number of lever presses during PR sessions (59±15), although it did significantly reduce lever presses during FR sessions (21±3). In addition, the pattern of intake was constant at the beginning of the sessions in both PR and FR schedules, regardless of the dose. Together these data suggest that EX4 inhibits consumption of a palatable high sweet/high fat reinforcer potentially through altering satiety.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26701752      PMCID: PMC5467700          DOI: 10.1016/j.pbb.2015.12.007

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  22 in total

1.  Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons.

Authors:  Niels Vrang; Curtis B Phifer; Michele M Corkern; Hans-Rudolf Berthoud
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-04-24       Impact factor: 3.619

2.  Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect.

Authors:  Stephanie Sisley; Ruth Gutierrez-Aguilar; Michael Scott; David A D'Alessio; Darleen A Sandoval; Randy J Seeley
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

Review 3.  Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy.

Authors:  N R Richardson; D C Roberts
Journal:  J Neurosci Methods       Date:  1996-05       Impact factor: 2.390

4.  GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake.

Authors:  Amber L Alhadeff; Laura E Rupprecht; Matthew R Hayes
Journal:  Endocrinology       Date:  2011-11-29       Impact factor: 4.736

Review 5.  Role of the glucagon-like-peptide-1 receptor in the control of energy balance.

Authors:  Matthew R Hayes; Bart C De Jonghe; Scott E Kanoski
Journal:  Physiol Behav       Date:  2010-03-10

6.  Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro.

Authors:  Prasad S Dalvi; Anaies Nazarians-Armavil; Matthew J Purser; Denise D Belsham
Journal:  Endocrinology       Date:  2012-02-14       Impact factor: 4.736

7.  Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose.

Authors:  Matthew R Hayes; Elizabeth G Mietlicki-Baase; Scott E Kanoski; Bart C De Jonghe
Journal:  Annu Rev Nutr       Date:  2014-04-10       Impact factor: 11.848

8.  Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats.

Authors:  Rafael R Schick; Jens P Zimmermann; Thomas vorm Walde; Volker Schusdziarra
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-06       Impact factor: 3.619

9.  Binge-type eating induced by limited access in rats does not require energy restriction on the previous day.

Authors:  Rebecca L Corwin
Journal:  Appetite       Date:  2004-04       Impact factor: 3.868

10.  The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size.

Authors:  Karen A Scott; Timothy H Moran
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-06-20       Impact factor: 3.619

View more
  3 in total

1.  Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats.

Authors:  Yafang Zhang; Michelle W Kahng; Jaclynn A Elkind; Vanessa R Weir; Nicole S Hernandez; Lauren M Stein; Heath D Schmidt
Journal:  Neuropsychopharmacology       Date:  2019-10-03       Impact factor: 7.853

2.  Activation of glucagon-like peptide-1 receptors reduces the acquisition of aggression-like behaviors in male mice.

Authors:  Jesper Vestlund; Qian Zhang; Olesya T Shevchouk; Daniel Hovey; Lundström Sebastian; Lars Westberg; Elisabet Jerlhag
Journal:  Transl Psychiatry       Date:  2022-10-13       Impact factor: 7.989

Review 3.  Ghrelin and Glucagon-Like Peptide-1: A Gut-Brain Axis Battle for Food Reward.

Authors:  Lea Decarie-Spain; Scott E Kanoski
Journal:  Nutrients       Date:  2021-03-17       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.